<DOC>
	<DOCNO>NCT02590952</DOCNO>
	<brief_summary>Epitinib ( HMPL-813 ) selective EGFR tyrosine kinase inhibitor . Epitinib demonstrate strong inhibitory effect multiple tumor overexpressed EGFR sensitive EGFR mutation pre-clinical setting . This first-in-human study conduct assess maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) , safety tolerability , pharmacokinetics ( PK ) , preliminary anti-tumor activity Epitinib .</brief_summary>
	<brief_title>A Phase I Study Epitinib ( HMPL-813 ) Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histopathology confirm solid tumor Failed standard treatment standard treatment uncontrolled , recurrent and/or metastatic advance tumor ( whatever previous surgery condition ) Age 1870 ECOG 02 , bad within 7days Life expect &gt; 12 week write informed consent form voluntarily For dose expansion cohort , subject must eligible follow inclusion criterion : EGFR sensitize mutation exon 19 deletion exon 21 ( L858R ) . Histologically cytologically confirm advanced NSCLC brain metastasis . No prior brain radiotherapy brain metastasis progress brain radiotherapy deliver assessed RECIST 1.1 . No prior EGFRTKI treatment . Or subject treat EGFRTKI develop brain lesion EGFRTKI therapy exist brain lesion progress stable extracranial lesion . Treatment failure prior systemic chemotherapy locally advance metastasized NSCLC intolerance chemotherapy . Or subject disease relapse treat adjuvant neoadjuvant chemotherapy . With least one measurable disease ( RECIST 1.1 ) . Lab test within 2 week enrol , AND ANC &lt; 1.5×10 9/L , platelet &lt; 75×10 9/L , Hb &lt; 9g/dL , Serum Total Bilirubins &gt; ULN , ALT/AST≥ULN without liver metastasis , ALT/AST≥2.5ULN liver metastasis Serum creatinine &gt; 1.5ULN creatinine clearance &lt; 40ml/min Diastolic systolic pressure≥140mmHg systolic diastolic pressure≥90mmHg whatever antihypertension drug use , Serum potassium &lt; 4.0mmol/L ( whenever potassium implement ) , serum calcium ( ionic albumintype calcium ) serum magnesium outside normal range ( whenever implement ) Within previous 4 week treat systemic antitumor therapy , radiotherapy , immune therapy , biological hormonal therapy , clinical trial . Unrecovered previous therapy relate toxicity CTCAE 0 1or unrecovered previous surgery Known dysphagia drug malabsorption Active infection acute pneumonia , hepatitis B immuneactive periodphase ocular surface diseases dry eye syndrome skin disease obvious symptom sign significant cardiovascular disease , include IIIV atrioventricular block , acute myocardial infarction within 6 month , significant angina Coronary artery bypass graft within 6 month Female patient pregnant feeding , childbearing potential patient pregnant test positive Any abnormal clinical laboratory patient unsuitable attend trial sine opinion investigator Patients unable comply protocol since significant psychological psychogenic abnormal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>safety , PK</keyword>
</DOC>